This corroborates well with a study conducted by Gulbache et al., in which ER−/GATA-3+ tumours had worse breast cancer survival (BCS) (p = 0.02) and a trend for worse overall survival (OS) (p = 0.05) compared to ER−/GATA-3− tumours [71]. This evidence concerns the gene GATA3 and neoplasm.